Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared a post on X:
“Tandem 2026: Key Advances in Cellular Therapy & Transplantation
The field is evolving – and this year’s Tandem Meetings highlighted where we’re headed next.
From next-generation CAR-T constructs to scalable allogeneic platforms, the focus is clear:
- Improve safety
- Accelerate manufacturing
- Expand access
- Strengthen supportive care
Highlights include:
- Novel CAR-T designs showing deep responses with encouraging safety profiles
- Dual-target strategies aimed at reducing relapse and toxicity
- Emerging off-the-shelf products moving closer to real-world feasibility
- Cellular platforms beyond traditional T cells
- Supportive-care data that may help optimize outpatient management
What stood out most? Not just innovation – but refinement. The science is becoming more precise, more practical, and more patient-centered.
For anyone following transplant and cellular therapy, these updates offer meaningful insight into where the field is moving next. Full highlights here.”
Other articles featuring Yan Leyfman on OncoDaily.